Efficacy of SVK in the treatment of Psoriasis

A randomized controlled trial to determine the safety and efficacy of Sivanarvembu Kuzhithailam (SVK) in the management of Kalanjagapadai (Psoriasis).

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/06/043139

Enrollment

Registered

2022-06-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Sivanarvembu Kuzhithailam: First arm will receive Sivanarvembu Kuzhithailam 5 drops BD internally for 90 days Intervention2: Sivanarvembu Kuzhithailam with Vetpalai Thailam: Third arm

Eligibility

Inclusion criteria

Inclusion criteria: Well defined nonindurated dry erythematous lesions with scaling A minimum PASI score of 12.0 at screening Psoriasis covering = 10% of total BSA Dermatology life quality index (DLQI) score at least 4 Duration of disease at least 6 months Plaque psoriasis clinically stable for at least 3 months prior to screening Body weight = 100 kg

Exclusion criteria

Exclusion criteria: Guttate, erythrodermic, or pustular psoriasis Clinically significant psoriasis flare during screening or at the time of enrolment History of any secondary skin infection Pregnancy or lactation Patients undergoing treatment for chronic illness Diabetes mellitus, Cardiovascular diseases, Tuberculosis, Hypertension etc Patient with a history of alcohol or drug abuse Candidate who had been previously treated (e.g., cyclosporine, corticosteroids, methotrexate)

Design outcomes

Primary

Measure	Time frame
No significant variation in the haematological, biochemical parameters. PASI Score: Response status at the end will be determined as follows: Responder: Any subject whose PASI score decreased = 50% from day 0 to day 46 and day 91. Partial responder: Any subject whose PASI score decreased = 30% but 50% from day 0 to day 46 and day 91. Non-responder: Any subject whose PASI score decreased 30% from day 0 to day 46 and 91st day. Timepoint: 0th day to 46th and 91st day	—

Measure

Time frame

No significant variation in the haematological, biochemical parameters. PASI Score: Response status at the end will be determined as follows: Responder: Any subject whose PASI score decreased = 50% from day 0 to day 46 and day 91. Partial responder: Any subject whose PASI score decreased = 30% but 50% from day 0 to day 46 and day 91. Non-responder: Any subject whose PASI score decreased 30% from day 0 to day 46 and 91st day. Timepoint: 0th day to 46th and 91st day

—

Secondary

Measure	Time frame
Dermatology Life Quality Index: Any subjects whose DLQI score increase 4 points and above. Mode of action can be simulated Timepoint: 0th day to 46th and 91st day	—

Countries

India

Contacts

Public ContactDr Rathinamala

Siddha Regional Research Institute

drrmala@gmail.com9445237368

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026